Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions



Rating:

Share or cite this content

Citations should be made in the following way:
G. Kuklina, E. Shmelev (Moscow, Russian Federation). Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome. Eur Respir J 2011; 38: Suppl. 55, 4414

Member's Comments

No comment yet.

Related content which might interest you: Effect of inhaled bronchodilator therapy on the bacterioexcretion and on the quality of life (LQ) of pulmonary TB patients with concomitant lung obstructive syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Treatment effect of inhaled prolonged bronchodilator therapy (IPBT) combined with inhaled glucocorticosteroids (IGCS) on respiratory symptoms and external respiratory function in MDR pulmonary TB patients with broncho-obstructive syndrome (BOS) Source: Annual Congress 2012 - New insights in the clinical management of lung diseases Year: 2012 Changes in the quality of life of pulmonary TB patients depending on the severity of bronchial obstruction when using standard antituberculosis therapy and inhaled bronchodilator therapy Source: Eur Respir J 2003; 22: Suppl. 45, 21s Year: 2003 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010 Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007 Tolerance test for inhaled antibiotics in patients with chronic bronchial infection Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018 Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma Source: Eur Respir J 2007; 30: Suppl. 51, 553s Year: 2007 Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004